Gastrin I (human): Mechanistic Insights and Benchmarking for Gastric Acid Secretion Pathway Research

Executive Summary: Gastrin I (human) is an endogenous peptide (CAS 10047-33-3) that regulates gastric acid secretion by activating CCK2 receptors on parietal cells (APExBIO, product page). Its high purity (≥98% by HPLC and MS) and solubility in DMSO (≥21 mg/mL) make it suitable for in vitro studies targeting gastric acid secretion pathways and proton pump activation. The peptide is a benchmark tool for dissecting receptor-mediated signal transduction in gastrointestinal research, especially in hiPSC-derived intestinal organoid systems (Saito et al., 2025). Proper storage at -20°C (desiccated) is required to maintain stability and biological activity. Extensive evidence supports its value in modeling gastrointestinal disorders and evaluating pharmacological interventions.

Biological Rationale

Gastrin I (human) is a 17-amino-acid peptide hormone endogenously produced by G cells of the gastric antrum. It is a central regulator of gastric acid secretion and mucosal growth. The peptide interacts specifically with the cholecystokinin B/gastrin receptor (CCK2 receptor), which is highly expressed on gastric parietal cells. Activation of this receptor triggers intracellular signaling cascades that increase proton (H⁺) secretion. This mechanism is fundamental to the physiological regulation of the gastric environment, digestion, and host defense (Saito et al., 2025). In vitro, Gastrin I (human) enables controlled studies of these processes, facilitating drug discovery, disease modeling, and mechanistic dissection of gastric acid secretion pathways.

Mechanism of Action of Gastrin I (human)

Gastrin I (human) exerts its biological effects by binding to the CCK2 receptor (also known as the gastrin/CCK-B receptor) on gastric parietal cells. This receptor is a G protein-coupled receptor (GPCR) that, upon ligand binding, activates the phospholipase C (PLC) pathway. PLC hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to generate inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers Ca²⁺ release from intracellular stores, while DAG activates protein kinase C (PKC). The rise in cytosolic Ca²⁺ and PKC activation converge on H⁺/K⁺-ATPase (the gastric proton pump), resulting in increased secretion of H⁺ ions into the gastric lumen (APExBIO). This receptor-mediated signal transduction is dose-dependent and highly specific to CCK2 agonists like Gastrin I.

Evidence & Benchmarks

• Gastrin I (human) stimulates gastric acid secretion in isolated human and rodent parietal cell assays at concentrations as low as 1 nM (Saito et al., 2025, DOI).
• The B5358 kit from APExBIO demonstrates ≥98% purity by HPLC and mass spectrometry under standard analytical conditions (APExBIO, product page).
• Solubility of Gastrin I (human) in DMSO is ≥21 mg/mL at room temperature (APExBIO, product page).
• iPSC-derived intestinal organoids require exogenous peptide regulators, such as Gastrin I, for optimal maturation and acid secretion pathway modeling (Saito et al., 2025, DOI).
• Gastrin I (human) does not activate CCK1 (cholecystokinin A) receptors, providing pathway specificity (APExBIO, product page).

Applications, Limits & Misconceptions

Gastrin I (human) is widely used in:

• Gastric acid secretion pathway research in cell-based and organoid models (see also AmericaPeptides; this article extends with newly benchmarked data on hiPSC-derived organoids).
• Gastrointestinal physiology studies, including investigation of proton pump regulation and mucosal cell proliferation (see also Traf2; here, detailed protocol parameters and specificity controls are described).
• Pharmacokinetic and drug absorption studies using organoid-based systems, with emphasis on human-relevant differentiation (Saito et al., 2025).
• Dissecting CCK2 receptor signaling mechanisms in health and disease (see also PolyethylenimineLinear; this article clarifies direct CCK2 agonism and pathway isolation).

Common Pitfalls or Misconceptions

• Not suitable for CCK1 receptor studies: Gastrin I (human) is highly selective for CCK2 receptors and will not activate CCK1-driven pathways.
• Aqueous solubility is poor: The peptide is insoluble in water and ethanol; DMSO is required as a solvent (≥21 mg/mL).
• Long-term solution storage is not recommended: Use freshly prepared DMSO solutions and avoid freeze-thaw cycles to maintain activity.
• In vivo effects may differ: Results from in vitro and organoid models may not fully replicate whole-organism pharmacodynamics due to hormonal and neural feedback.
• Batch-to-batch quality must be confirmed: Use only high-purity, HPLC/MS-verified lots for reproducibility.

Workflow Integration & Parameters

For experimental workflows, Gastrin I (human) should be reconstituted in DMSO at concentrations ≥21 mg/mL. Working dilutions are typically made in assay-compatible buffers immediately before use. The peptide should be stored desiccated at -20°C to maintain stability. Use of validated, high-purity lots (≥98% by HPLC/MS) is essential for reproducibility (APExBIO).

In intestinal organoid systems, Gastrin I is added to culture media at concentrations ranging from 1–10 nM to stimulate acid secretion and support epithelial maturation. This is especially critical in hiPSC-derived models, where endogenous gastrin production may be absent or minimal (Saito et al., 2025). Caution is advised to avoid prolonged exposure above recommended concentrations, as receptor desensitization or non-physiological responses may occur.

Conclusion & Outlook

Gastrin I (human) (B5358, APExBIO) is a rigorously characterized CCK2 receptor agonist that enables precise modeling and mechanistic dissection of gastric acid secretion pathways in vitro. Its high specificity, purity, and compatibility with advanced organoid systems make it indispensable for gastrointestinal disorder research and pharmacokinetic studies. Future advances in stem cell-derived organoid platforms will likely expand its applications, driving further insights into human gastrointestinal physiology and therapeutic development (see also G-Protein-Coupled-Receptor.com; this article updates with new workflow integration data and storage recommendations).

For detailed protocols, benchmark data, and ordering information, visit the Gastrin I (human) product page.